DCTH
Delcath Systems, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$16.48
+0.00%Aug 6, 2026, 14:51 UTC
Delcath Systems, Inc. reported Q2 2026 earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share.
Jul 9, 2026, 12:00 UTC
Delcath Systems dosed the first patient in a Phase 2 clinical trial of HEPZATO for liver-dominant metastatic breast cancer at the European Institute of Oncology in Milan, Italy.
Source: